Your session is about to expire
← Back to Search
High-Dose Vitamin C + Low-Dose Melphalan for Multiple Myeloma
Study Summary
This trial is testing if a low dose of melphalan combined with high doses of ascorbate acid is safe and effective in treating patients who have multiple myeloma that has returned or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not a candidate for known effective treatments for my relapsed or refractory multiple myeloma.My condition worsened after 3 or more treatments.I am currently taking Coumadin (warfarin).I have had kidney stones made of oxalate or multiple kidney stones before.Women who could become pregnant must have a negative pregnancy test before starting the study.I do not have any severe health conditions that could threaten my life.I have been diagnosed with HIV.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I use a glucometer for my diabetes management.I have been diagnosed with multiple myeloma.I have been treated with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody.You must have a detectable and quantifiable medical condition according to specific guidelines.My organs are functioning well.I have G6PD deficiency.You are allergic to ascorbic acid or melphalan.I have another cancer that can be treated without chemotherapy.I am able to get out of my bed or chair and move around.
- Group 1: Low dose melphalan + high dose ascorbate acid (HDAA)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what health conditions is Ascorbate typically prescribed?
"Vitamin A deficiency is regularly treated with Ascorbate. This same medication can be beneficial for addressing a variety of other maladies, including catarrh, vitamin insufficiency and amyloidosis."
Are there any adverse effects associated with ingesting Ascorbate?
"Currently, the evidence of Ascorbate's safety is limited, therefore giving it a score of 1 on our scale. This assessment was made due to this being an early Phase 1 trial with only meager data pointing towards efficacy and security."
What is the sample size of this research project?
"Yes, clinicaltrials.gov confirms that this trial is actively looking for participants to join the study, which was first posted on March 5th 2019 and last updated on December 31st 2021. As of now, only 9 patients are being sought at a single site."
Is enrollment for this experiment open at this moment?
"Affirmative. Clinicaltrials.gov states that the research study, which was initially posted on March 5th 2019, is now recruiting participants. A total of 9 individuals are required to be recruited from 1 site."
Share this study with friends
Copy Link
Messenger